Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…Abstract Number: 2365 • 2019 ACR/ARP Annual Meeting
Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
Background/Purpose: Rheumatoid arthritis (RA) patients have a high prevalence of cardiovascular comorbidities including diabetes mellitus (DM). Past studies have suggested a potential beneficial effect of…Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…Abstract Number: 2773 • 2019 ACR/ARP Annual Meeting
Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable remission may be feasible in a subset of patients…Abstract Number: 2874 • 2019 ACR/ARP Annual Meeting
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.…Abstract Number: 37 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis
Background/Purpose: Intestinal microbial dysbiosis in patients with rheumatoid arthritis (RA) has raised the interest in studying the role of intestinal microbes in the pathogenesis of…Abstract Number: 118 • 2019 ACR/ARP Annual Meeting
Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients
Background/Purpose: Regulatory T cells (Treg) are necessary for immune homeostasis but are functionally deficient in inflammatory/autoimmune diseases such as rheumatoid arthritis (RA). On the other…Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…Abstract Number: 325 • 2019 ACR/ARP Annual Meeting
Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Background/Purpose: Sarcopenia, the loss of skeletal muscle mass, is associated with adverse individual physical and metabolic changes contributing to morbidity and mortality. Sarcopenia is a…Abstract Number: 455 • 2019 ACR/ARP Annual Meeting
Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Background/Purpose: Over the past years, novel biomarkers have been described in rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD) enzymes. Anti-PAD4 IgG…Abstract Number: 494 • 2019 ACR/ARP Annual Meeting
Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Background/Purpose: The Targeting Immune Responses for Prevention of RA (TIP-RA) Collaborative prospectively studies individuals at high risk for developing RA because of serum ACPA positivity…Abstract Number: 537 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…Abstract Number: 842 • 2019 ACR/ARP Annual Meeting
Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease
Background/Purpose: The frequency of pulmonary involvement in rheumatoid arthritis varies between 7-35%. The most important cause of death in RA patients is lung disease in…Abstract Number: 960 • 2019 ACR/ARP Annual Meeting
Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are the main diagnostic and pathologic autoantibodies in rheumatoid arthritis. However, autoantibodies develop against proteins with…Abstract Number: 1172 • 2019 ACR/ARP Annual Meeting
The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging
Background/Purpose: Many RA patients in clinical remission have evidence of bone marrow edema (BME) on magnetic resonance imaging (MRI), with radiographic bone damage progression appearing…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 56
- Next Page »